ESTRO 2023 - Abstract Book

S743

Monday 15 May 2023

ESTRO 2023

Cohort characteristics

N=68

Gender Male Female

54 14

Age (years) Median (range)

68 (50 - 86) 8 60

<60 ≥ 60

Cirrhosis Yes No

62 6

Etiology HCV HBV Alcohol liver disease NAFLD Other

22 6 21 30 5 50 8 9 1 6 41 21

ECOG 0 1 2 Not recorded

Child-Pugh Score Non-cirrhotic

A5 A6

Baseline AFP <20 ≥ 20

54 14

Tumor size, cm ≤ 2 >2 - ≤ 5

20 48

Conclusion SBRT is a well-tolerated, definitive first-line treatment option in patients with BCLC stage 0/A, single HCC with high rates of local control and warrants further study in the treatment naïve setting. The ongoing multicentre TROG 21-07 study is randomising non-surgical patients with solitary HCC ≤ 3cm to SBRT or thermal ablation and an additional “ablation ineligible” cohort with HCC ≤ 5cm to SBRT or transarterial therapies (ACTRN1262100144875).

Poster Discussion: New technologies for treatment planning and dose verification

PD-0897 In vitro dosimetry for biological effectiveness assessment of targeted-alpha-therapy A. Doudard 1 , A. Corroyer-Dulmont 2 , C. Jaudet 3 , M. Bernaudin 4 , S. Valable 5 , X. Ledoux 1 , A. Frelin-Labalme 1